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Abstract
Introduction Cerebral atrophy is a compound measure of the
neurodegenerative component of multiple sclerosis (MS) and
a conceivable outcome measure for clinical trials monitoring
the effect of neuroprotective agents. In this study, we evaluate
therateofcerebralatrophyina6-monthperiod,investigatethe
predictive and explanatory value of other magnetic resonance
imaging (MRI) measures in relation to cerebral atrophy, and
determine sample sizes for future short-term clinical trials
using cerebral atrophy as primary outcome measure.
Methods One hundred thirty-five relapsing–remitting mul-
tiple sclerosis patients underwent six monthly MRI scans
from which the percentage brain volume change (PBVC)
and the number and volume of gadolinium (Gd)-enhancing
lesions, T2 lesions, and persistent black holes (PBH) were
determined. By means of multiple linear regression analy-
sis, the relationship between focal MRI variables and
PBVC was assessed. Sample size calculations were
performed for all patients and subgroups selected for
enhancement or a high T2 lesion load at baseline.
Results A significant atrophy occurred over 6 months
(PBVC=−0.33%, SE=0.061, p<0.0001). The number of
baseline T2 lesions (p=0.024), the on-study Gd-enhancing
lesion volume (p=0.044), and the number of on-study
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DOI 10.1007/s00234-009-0645-1PBHs (p=0.003) were associated with an increased rate of
atrophy. For a 50% decrease in rate of atrophy, the sample
size calculations showed that approximately 283 patients
per arm are required in an unselected sampled population
and 185 patients per arm are required in a selected
population.
Conclusion Within a 6-month period, significant atrophy
can be detected and on-study associations of PBVC and
PBHs emphasizes axonal loss to be a driving mechanism.
Application as primary outcome measure in short-term
clinical trials with feasible sample size requires a potent




Brain tissue loss is a prominent feature in the pathology of
multiple sclerosis (MS) and occurs at a significantly higher
rate in patients with MS compared to the normal aging brain
[1, 2]. In greater part, this phenomenon has been attributed
to neuronal and axonal loss in both lesions [3] and normal-
appearing brain tissue [4, 5] and, therefore, cerebral atrophy
is recognized as a global marker of the neurodegenerative
components of MS [6]. Magnetic resonance imaging (MRI)
detects the rate of cerebral atrophy in vivo in a sensitive and
reproducible manner which, together with the substantial
correlation with later clinical disability [7], makes cerebral
atrophy a conceivable outcome measure for clinical trials
measuring the efficacy of neuroprotective agents.
Previous studies in untreated patients with relapsing–
remitting multiple sclerosis (RRMS) revealed fairly stable
annualized brain volume decreases of approximately 0.6%
to 1.35%, determined over moderate (1 year) to long
(3 years) periods of follow-up [6]. Fewer studies, however,
assessed the rate of cerebral atrophy for shorter periods of
follow-up, and did so with various measures of atrophy. In
a 3-month study of 138 RRMS patients, a significant
decrease in atrophy rate was detected using brain paren-
chymal fraction as atrophy measure [8], whereas in a
similar study using 30 RRMS patients, no significant
decrease was found [9]. In another study, patients in the
placebo arm of a clinical trial with a follow-up duration of
9 months showed a significant decrease in brain volume
measuredbyassessmentofsevencontiguousbrainslices[10].
Although these studies indicate that cerebral atrophy is
detectable on the shorter term, little is known about the
statistical power and required sample size for detecting
significant treatment effects in short-term clinical trials in
MS using cerebral atrophy as primary outcome measure. In
a recent paper, sample sizes for various MRI brain atrophy
measures in RRMS patients were estimated for longer
periods of follow-up (1–3 years) and showed that the so-
called SIENA technique, an automated MRI atrophy
measurement, yielded the most promising results [11].
Following these findings, in the present study, we aim to
assess the feasibility of using SIENA-based cerebral
atrophy as primary outcome measure in short-term phase
2 clinical trials in MS. First, we evaluate the rate of atrophy
with SIENA in a large cohort of RRMS patients without
effective treatment over a 6-month period. Then, the
predictive and explanatory value of MRI outcome measures
in relation to cerebral atrophy is assessed and, lastly, power
calculations based on the detected rate of atrophy are
performed to determine the number of patients required in
short-term placebo-controlled clinical trials using the rate of
cerebral atrophy as primary outcome measure.
Methods
Patients
Our analyses were performed with data derived from the
oral interferon beta-1a (IFNB-1a) study [12]. In this study,
173 patients with active RRMS received various doses of
IFNB-1a or placebo orally every other day for 6 months.
No clinical effect (median expanded disability status scale
[EDSS] was 2.0 in all treatment groups at screening and at
the end of study; approximately two thirds of patients in
each group remained relapse-free) or MRI effect (median
cumulative numbers of newly active lesions over 6 months
were 4.0 in the placebo and 0.6 MIU groups, compared
with 7.5 and 9.0 in the 0.06 and 6 MIU groups [no
significant differences]) of any dose could be observed,
including low neopterin levels in a subgroup of 21 patients
and the absence of neutralizing antibodies in a subgroup of
24 patients; oral IFNB-1a was assumed to be biologically
inactive and the cohort is regarded as a cohort representa-
tive of the placebo arm of a randomized trial.
MRI acquisition and analysis
MRI of the brain was performed at baseline and on six
subsequent monthly MRI scans. Scans were performed,
including a dual-echo, T2-weighted, spin-echo, or turbo/fast
spin-echo (TR/TE of 2,000–3,000/20–40 and 60–100 ms)
and a T1-weighted spin-echo (TR/TE of 400–700/5–25 ms),
both after administration of 0.1 mmol/kg gadolinium (Gd)-
DTPA intravenously, with a field of view of 25 cm and a
256×256 matrix resulting in roughly 1×1 mm pixel size.
Images were acquired in 2×23 interleaved sections with a
3-mm thickness and a 3-mm gap, in accordance with
published guidelines for the use of MRI in clinical trials
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measures, the baseline normalized brain volume (NBV) and
percentage brain volume change (PBVC) over 6 months
was assessed using the automated segmentation-based
techniques SIENAX and SIENA, respectively [14].
Statistical analysis
Primary outcome measure was the atrophy rate over
6 months, which followed the normal distribution. Compar-
isons for demographic and MRI characteristics between
included and excluded patients were assessed by indepen-
dent samples t tests and Mann–Whitney U test for
continuous variables and the nonparametric binomial test
for proportions. Correlations between variables were
assessed with Pearson's R. By means of multiple linear
regression analysis (SPSS version 13.0; SPSS Inc.,
Chicago, IL, USA), the predictive and explanatory value
of baseline and on-study clinical and MRI variables for the
PBVC over 6 months was determined. Independent
variables included baseline NBV, presence of a Gd-
enhancing lesion at the baseline scan, baseline number
and volume of Gd-enhancing lesions, baseline number and
volume of T2 lesions, on-study number and volume of Gd-
enhancing lesions, on-study number and volume of T2-
enhancing lesions, and on-study number of persistent black
holes (PBH). A PBH was defined as new enhancing lesions
or new T2 lesions (hyperintense on pd/T2, non-enhancing
on T1) that appeared at month 1, 2, or 3 and became a black
hole at months 4, 5, and 6, respectively [15]. Linearity in
relation to PBVC was checked for all variables and natural
log transformation was applied if a nonlinear relationship
was found (to account for zero lesions, 1 was added prior to
transformation). All effects were corrected for age, disease
duration, and sex, and statistical testing was performed with
a two-sided test level of 5% with an additional Bonferroni
correction for multiple testing.
Sample size calculations
Sample size estimates were based on the standard formula,
assuming the rate of cerebral atrophy to be normally
distributed:
n1 ¼ n2 ¼
2 z1 a
2 þ z1 b
 2
s2
u2   u1 ðÞ
2 ð1Þ
with σ
2 as the standard deviation and μ1 and μ2 as the mean
brain volume atrophy in the placebo and treatment groups,
respectively.
Sample sizes were determined for a trial duration of
6 months to detect a treatment effect of 50% to 90%
reduction in atrophy rate at 80% and 90% power with and
without taking into account a 5% dropout rate and a two-
tailed significance level of 5%. Since atrophy rates of
healthy controls were unavailable, we assumed a 100%
treatment effect to correspond to zero brain volume loss.
Treatment effects were assumed immediate and constant.
To assess the impact of patient selection at baseline on the
required sample size, subgroup analyses were performed
for patients selected for the presence of an enhancing lesion
at baseline and patients selected for a high T2 lesion load
(greater than median) at baseline.
Results
Baseline demographics and MRI characteristics of the
included and excluded patients are given in Table 1. From
the original 173 patients, four patients lacked MRI assess-
Characteristic Included Excluded p value
General
n 135 34
Sex (female/male) 98/37 25/9 0.44
Age, mean (SD) 35.8 (8.6) 33.7 (7.4) 0.18
Disease duration in years, mean (SD) 6.6 (5.5) 5.3 (4.5) 0.19
Baseline EDSS, median (IQR) 2.0 (1.5–3.5) 2.0 (1.5–2.5) 0.15
MRI
Number of patients with ≥1 T1 Gd+ lesion (%) 80 (59) 19 (56) 0.07
Number of Gd+ lesions, mean (SD) 2.40 (4.3) 2.0 (3.4) 0.39
Volume of Gd+ lesions in cm
3, mean (SD) 0.18 (0.6) 0.12 (0.27) 0.54
Number of T2 lesions, mean (SD) 89.1 (74.3) 102.8 (70.0) 0.33
Volume of T2 lesions in cm
3, mean (SD) 7.39 (7.6) 6.30 (5.7) 0.43
Volume of T2 lesions in cm
3, median (SD) 5.02 (7.6) 5.0 (5.7) 0.43
NBV in cm
3, mean (SD) 1,449 (77.5) 1,481 (71.5) 0.49
Table 1 Baseline demographics
and MRI characteristics.
Baseline demographics and MRI
characteristics of the included
and excluded patients, with the
accompanying p value for the
difference between both groups
SD standard deviation, IQR
interquartile range, EDSS
expanded disability status scale,
Gd+ cadolinium-enhancing
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included in the analyses. From the remaining 169 patients,
the rate of cerebral atrophy could be assessed in 135
patients. From the 34 excluded patients, 12 patients from
the site Graz were not analyzed, and for 22 patients, the
available scans were rejected due to image quality. Patients
had a mean age of 35.8 years (SD=8.6), a mean disease
duration of 6.6 years (SD=5.5), and a median baseline
EDSS score of 2.0 (interquartile range=1.5–3.5). No
significant differences in disease duration, age, EDSS
score, and baseline MRI characteristics were observed
between the studied group and the 34 excluded patients.
The mean NBVat baseline was 1,494 ml (SD=77.0). NBV
was moderately correlated with the EDSS score at baseline
(R=−0.32, p<0.0001) and T2 lesion load and number of T2
lesions at baseline (R=−0.38, p<0001 and R=−0.29, p=
0.01, respectively) and weakly correlated with age (R=
−0.19, p=0.03; data not shown).
On-study MRI outcome measures are shown in Table 2.
For the 6-month follow-up period, a significant loss of
brain volume was detected, comparing the baseline scan
with the month 6 scan (PBVC=−0.33%, SD=0.70, p<
0.0001). Patients selected for the presence of an enhancing
lesion at baseline or those selected for a high T2 lesion load
at baseline tended to have a more pronounced atrophy
(PBVC=−0.39%, SD=0.68 and PBVC=−0.42%, SD=
0.73, respectively), compared with patients without an
enhancing lesion at baseline or a low T2 lesion load at
baseline (PBVC=−0.25%, SD=0.75 and PBVC=−0.25%,
SD=0.69, respectively).
Table 3 shows the key results of the regression analyses
assessing the relationship between MRI variables and PBVC.
With a Bonferroni-corrected alpha of 0.005, the number of
PBHs (p=0.003) was significantly associated with an
increased rate of atrophy, whereas the number of T2 lesions
at baseline (p=0.024) and the cumulative volume of
enhancing lesions (p=0.044) failed to predict a higher rate
of atrophy over 6 months. The accompanying explained
variances are low, indicating that cerebral atrophy is
marginally explained by variation in lesional measures alone.
The estimated sample sizes are shown in Table 4.
Compared to the estimates based on patients unselected at
Table 2 On-study MRI measures.











n 135 80 55 67 68
Cumulative number of Gd+ lesions, mean (SD) 10.8 (13.9) 16.2 (15.4) 2.93 (5.3) 16.3 (16.6) 5.4 (7.5)
Cumulative volume of Gd+ lesions in cm
3, mean (SD) 1.39 (2.07) 2.10 (2.35) 0.35 (0.84) 2.18 (2.54) 0.61 (1.0)
On-study T2 lesion volume change in cm
3, mean (SD) +0.18 (2.01) +0.15 (2.38) +0.21 (1.33) +0.16 (2.75) +0.20 (0.77)
Cumulative number of PBH, mean (SD) 1.71 (42.9) 2.73 (3.4) 0.24 (0.6) 2.6 (3.6) 0.8 (1.5)
PBVC, mean (SD) −0.33 (0.70) −0.39 (0.67) −0.25(0.75) −0.42 (0.72) −0.25 (0.69)
Percentage of inactive patients
a 18 5 36 10 25
On-study MRI measures for whole cohort and subgroups selected for the presence or absence of an enhancing lesion at baseline or a high or low
T2 lesion load (defined as above and below the median=5.02 cm
3 T2 lesion load, respectively) at baseline
Gd+ gadolinium-enhancing, SD standard deviation, PBH persistent black hole, PBVC percentage brain volume change
aNo on-study Gd+ lesions
Time of measurement MRI variable Regression coefficient p value R
2
Baseline NBV 0.304 0.802 0.004
Gd+ lesion number −0.108 0.144 0.018
Gd+ lesion volume −0.028 0.252 0.013
T2 lesion number −0.175 0.024 0.042
T2 lesion volume −0.108 0.069 0.028
On-study Gd+ lesion number −0.073 0.160 0.016
Gd+ lesion volume −0.044 0.044 0.033
T2 lesion number −0.003 0.220 0.013
T2 lesion volume −0.112 0.060 0.028
PBH −0.064 0.003 0.067
Table 3 Regression analysis
results.
Results of univariate multiple
linear regression analysis for the
relation between PBVC and
predictive/explanatory MRI
variables. All models were
corrected for age, sex, and
disease duration
NBV normalized brain volume,
Gd+ gadolinium-enhancing,
PBH persistent black hole
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as selection for a high T2 lesion volume at baseline were of
favorable influence on the number of required patients. The
calculations show that, for a treatment effect of 50%
decrease in rate of atrophy, approximately 283 patients
per arm are required when no selection criterion is applied
and 185 when patients were selected for a high T2 lesion
load at baseline, whereas for a 70% decrease in rate of
atrophy, 144 patients per arm are required in a unselected
cohort and 94 per arm in a selected cohort.
Discussion
As a compound measure of the overall destruction,
preservation, and repair of brain tissue in MS patients,
cerebral atrophy encompasses both neuroaxonal loss as
well as the processes of demyelination, remyelination,
gliosis, and edema. The present study shows that the rate
of cerebral atrophy can be detected within a 6-month period
and, when applied as primary outcome measure in short-
term clinical trials with feasible sample size, requires a
potent drug to obtain sufficient power.
Compared to sample size estimates for trials using
atrophy measured with SIENA over longer periods of
follow-up, the present sample sizes prove to be larger. To
detect a 50% decrease in atrophy rate, trials for RRMS
patients at 90% power showed approximately 69 patients
per arm to be required over a 1-year follow-up period and
40 patients per arm over a 3-year follow-up period [11],
whereas for trials for secondary progressive multiple
sclerosis with 1-year follow-up, 56 patients per arm are
required [16]. The lower sample sizes in these studies are
explained by the larger atrophy rates due to larger trial
durations and the accompanying larger detectable effect
sizes. Also, detection of atrophy over short intervals may be
prone to increased measurement errors leading to a greater
variability of the atrophy measure, thereby requiring larger
subject numbers than would be expected in a longer-
interval study. Since SIENA proved to accomplish larger
statistical power due to greater measurement precision
compared to other measures of atrophy [11], the current
sample size estimates are likely the optimal achievable
numbers for trials of short duration.
When interpreting the current sample sizes, some con-
siderations should be taken into account. First, the calcu-
lations assumed a 100% treatment effect to resemble zero
loss of brain volume, whereas healthy controls are known to
experience a small amount of brain volume loss. For
comparison, a previous study showed a PBVC of 0.11%
(0.30) within healthy controls for a follow-up duration of
1 year [11]. When taken into account, a larger sample size
will be required to detect a similar treatment effect. Second,
the treatment effects are assumed to be effective from onset
and constant over time. When this assumption is not met
and a compound takes time to become maximally effective,
the detected effect sizes will decrease and subsequently
increase the required sample size. Wallerian degeneration
initiated by axonal damage prior to treatment, for example,
might result in a delay of the true effect caused by the
already ongoing atrophic processes at initiation of the
drug. Another important consideration is the confounding
effect of other factors influencing brain volume such as
demyelination, remyelination, gliosis, and inflammation.
In particular, the resolution of edema and inflammation
induced by anti-inflammatory agents, a process known as
“pseudoatrophy” [6], can cause loss of brain volume and
cloud the measurement of true tissue loss. In order to
measure a true neuroprotective effect, especially within a
shorter period of time, a future trial might assess the
Baseline selection criteria Power Treatment effect size (% reduction in
atrophy rate)
50% 60% 70% 80% 90%
No selection criteria at baseline 80% 283 196 144 110 87
80% (5% dropout) 297 207 152 116 92
90% 378 262 193 148 117
90% (5% dropout) 398 276 203 155 123
Presence of an enhancing lesion 80% 191 133 97 75 59
80% (5% dropout) 201 140 103 78 62
90% 255 177 130 100 79
90% (5% dropout) 269 187 137 105 83
High T2 lesion load (greater than
median, >5,024 mm
2)
80% 185 128 94 72 57
80% (5% dropout) 194 135 99 76 60
90% 247 171 126 96 76
90% (5% dropout) 260 180 133 101 80
Table 4 Sample size estimates.
Number of patients per treat-
ment arm necessary to perform
parallel group designed trials
with statistical powers of 80% or
90%, with and without taking
into account a 5% dropout rate,
to detect treatment effects rang-
ing from 50% to 90%
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add-on therapy to immunomodulatory-treated patients in
both arms of the trial. Such a design, however, will likely
result in higher sample sizes because of decreased rates of
cerebral atrophy in the groups compared.
To partly overcome the aforementioned limitations, a
more effective trial design would be to perform a run-in
period of, e.g., 3 months in which the neuroprotective
compound is administered and subsequently perform the
short-interval atrophy assessment, thereby providing the
opportunity for the applied compound to become maximal-
ly effective and confounding processes initiated prior to the
trial to wane off.
An advantage of our study is that the present calculations
are applicable in multicenter trials since the underlying data
were obtained in multiple centers, with the accompanying
variability caused by varying scanners and analyses. Also,
we found a moderate but highly significant PBVC of
−0.33% in a group of untreated RRMS patients within a
period of 6 months. When annualized, this rate is well
within the range of previous results (0.6–1.35%/year [6])
which enhances the generalizability of the sample size
estimations since the calculations have not been biased by
an atrophy rate at the higher end of the range.
A possible gain in statistical power for shorter-termed
trials using cerebral atrophy as primary outcome measure
might be achieved by adding multiple scanning time points
to a trial. A recent study showed that, by placing additional
scans towards the start and end of the trial, reductions in
total variance and hence reductions in trial size of 41%
could be achieved in patients with Alzheimer disease, using
the brain boundary shift integral method for determining
the rate of cerebral atrophy [17]. In particular, due to the
within-subject variance contributing more to the overall
variance at short intervals, acquiring multiple scans has
more impact in shorter studies. Although relatively smaller
gains in power can be expected from adding time points for
more precise measures such as SIENA, the effect on the
required sample size should definitely be explored in future
multi-time point MS atrophy data.
The on-study association of the rate of atrophy and the
number of PBHs suggest axonal loss to be one of the
driving mechanisms of brain volume loss in MS patients.
Previous studies showed the on-study volume of black
holes to be closely related to supratentorial brain volume
[18] and the baseline volume of black holes to be
significantly correlated with subsequent development of
atrophy [10, 19]. In contrast, the present study was not able
to show a significant relationship between both Gd
enhancement activity and T2 lesion load and changes in
brain volume as shown in previous studies [8, 10, 19, 20].
These findings, together with the current results, show that
the associations between focal tissue changes and atrophy
are moderate at best over a relatively long period of follow-
up and weaken within shorter amounts of time, most
probably due to the noise introduced by the increased
variability in the measurements and that focal tissue
changes in MS only partly explain atrophy development.
This also emphasizes the added value of cerebral atrophy as
a measure of the overall destruction of neuronal tissue,
encompassing not only measurable focal destruction but
also unaccounted diffuse destruction.
The detectability of atrophy on the short term has been
attributed to the measure of activity of the patients assessed
within a cohort. Hardmeier et al. [8], who found a
significant atrophy rate within 3 months, stated that their
finding most likely reflected the natural history of a very
active group of RRMS patients with well-established
disease and could explain the absence of atrophy in
comparable short-termed studies [9, 21]. The current study
population underwent partly MRI-based selection criteria at
baseline and can be regarded as an active cohort of MS
patients, shown by the increase in T2 lesion load and Gd-
enhancing lesion number and volume over the study period
and the high proportion of active patients. The influence of
the measure of activity of patients on the rate of atrophy is
also reflected when the subgroups based on the applied
baseline selection criteria are compared (Table 2). Although
a more active cohort might influence the generalizability
compared to a more random sampled cohort of patients and
selection criteria make it more difficult to recruit subjects,
the trade-off is a larger sample size being required when
using unselected patients.
In conclusion, our finding suggests that the rate of
cerebral atrophy is a detectable outcome measure in short-
term clinical trials in RRMS and applicable in terms of
study power while a potent drug is applied.
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